GOODWILL, IPR AND D AND OTHER INTANGIBLE ASSETS, NET (Details 2) (USD $)	12 Months Ended							1 Months Ended					12 Months Ended						12 Months Ended	1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Patents	Dec. 31, 2012 Patents	Dec. 31, 2013 Acquired technology rights	Dec. 31, 2012 Acquired technology rights	Oct. 31, 2013 Optimer	Oct. 31, 2013 Optimer Contract intangibles	Sep. 11, 2013 Trius	Dec. 31, 2013 Tedizolid phosphate	Sep. 30, 2013 Tedizolid phosphate Trius	Dec. 31, 2013 Bevenopran (formerly known as CB-5945)	Dec. 31, 2012 Bevenopran (formerly known as CB-5945)	Dec. 31, 2013 Ceftolozane/tazobactam (formerly known as CXA-201) for HABP and VABP	Dec. 31, 2012 Ceftolozane/tazobactam (formerly known as CXA-201) for HABP and VABP	Dec. 31, 2013 Ceftolozane/tazobactam (formerly known as CXA-201) for cUTI and cIAI	Dec. 31, 2012 Ceftolozane/tazobactam (formerly known as CXA-201) for cUTI and cIAI	Dec. 31, 2013 ENTEREG	Oct. 31, 2013 DIFICID Optimer
Other intangible assets, net
Total IPR&D	$ 896,400,000	$ 272,700,000								$ 659,000,000	$ 659,000,000	$ 659,000,000	$ 43,400,000	$ 78,700,000	$ 174,000,000	$ 174,000,000	$ 20,000,000	$ 20,000,000
IPR&D asset (bevenopran)													43,400,000
Impairment charges recorded	35,300,000	38,700,000											35,300,000	38,700,000
Finite-lived intangible assets
Other intangible assets, gross	791,427,000	194,427,000		2,627,000	2,627,000	788,800,000	191,800,000
Less: accumulated amortization				(2,493,000)	(2,431,000)	(67,868,000)	(39,166,000)
Acquired finite-lived other intangible assets								597,000,000	36,000,000											561,000,000
Period of amortization																			9 years
Amortization expense	28,800,000	20,900,000	3,500,000
Estimated aggregate amortization of intangible assets
2014	64,741,000
2015	64,741,000
2016	63,460,000
2017	62,221,000
2018	62,221,000
2019 and thereafter	403,682,000
Total	$ 721,066,000	$ 152,830,000